New targeted drug shows promise for Hard-to-Treat cancers
NCT ID NCT05161390
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a new drug called LM-302 in 153 people with advanced solid tumors that have a specific protein called CLDN18.2. The drug is designed to target and kill cancer cells while sparing healthy ones. The main goals were to check safety, find the right dose, and see early signs of effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LM-302 (an antibody-drug conjugate targeting CLDN18.2)
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific marker called CLDN18.2.
- What could go wrong
- This is an early-phase trial, so the drug may not work or could cause serious side effects. Results are preliminary and need confirmation in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?